Does elevated lipoprotein(a) increase atherosclerotic cardiovascular disease risk independent of LDL cholesterol?

Lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD), including coronary heart disease and heart failure. Unlike many other lipid markers, Lp(a) levels are predominantly determined by an individual's genetic profile rather than lifestyle or environmental factors.

Clinical and effectiveness evidence

Extensive genetic and epidemiological research confirms that elevated Lp(a) levels significantly increase cardiovascular risk.

• Independent Risk Pathway: Mendelian randomization studies involving large datasets like the UK Biobank show that elevated Lp(a) increases the risk of coronary artery disease (OR 1.237 per SD increase) and heart failure.
• Persistent Risk: This risk remains significant even in individuals who have achieved low LDL-cholesterol (LDL-C) levels through standard therapy. Factorial analyses suggest that the cardiovascular benefit of lowering Lp(a) by ~100 mg/dL is comparable to lowering LDL-C by 38.67 mg/dL.
• Thresholds: Clinical guidelines, such as those from the European Atherosclerosis Society (EAS), identify levels above 50 mg/dL as a key "risk intensifier" that signals residual risk not captured by traditional lipid panels.

Mechanistic explanations

Lp(a) is composed of an LDL-like particle covalently bound to apolipoprotein(a) [apo(a)], and its pathogenicity is linked to its unique structure.

• Genetic Dominance: Approximately 75-95% of the variance in circulating Lp(a) levels is determined by the LPA gene locus.
• KIV-2 Copy Number Variation: The primary driver of these levels is the Kringle IV type 2 (KIV-2) copy number variation. A lower number of KIV-2 repeats results in smaller apo(a) isoforms, which are synthesized and secreted more efficiently, leading to higher plasma concentrations.
• Molecular Variants: Specific single nucleotide polymorphisms (SNPs), such as rs41272114, can significantly lower levels by disrupting apo(a) synthesis. While minor influences from IL-6 inflammatory signals and DNA methylation exist, the LPA gene remains the overwhelming determinant.

Bottom line

Elevated Lp(a) is a causal, genetically determined risk factor for ASCVD that operates independently of LDL-C. Because levels are largely fixed by the LPA gene, measuring Lp(a) provides critical information for identifying residual cardiovascular risk that standard lipid tests may miss.